

STIC-ILL

11/12/12

From:
Sent:
To:
Subject:

Schmidt, Mary
Thursday, December 12, 2002 1:36 PM
STIC-ILL
more references 09/122,588

424040

Slepushkin et al, J Biol. Chem., Jan 24, 1997, 272, 4, p2382-8.
Brown et al, Current opinion in rheumatology, nov. 1996, vol.8, n. 6, p539-43.
Konopka et al, biochimica et biophysica acta, jul. 24, 1996, 1312, 3, 186-96.
sioud, european j. of immunology, may 1996, 26, 5, p1026-31.
gu et al., circulation research, jul. 1995, 77, 1, p14-20.
de young et al. biochemistry, 10/11/94, 33, 40, 12127-38.
snyder et al. blood, jul. 15, 1993, 82, 2, 600-5.
taylor et al. nucleic acids research, 9-11-92, 20, 17, 4559-65.
rossi et al., aids research and human retroviruses, 2-92, 8, 2, 183-9.
sioud et al., journal of molecular biology, feb. 20, 1992, 223 (4), 831-5.
lasic dd, abstracts of papers american chemical society 213, 1-3, pbiot 1, 1997
schuster et al., drugs of today 32, 8, 653-661, 1996.
sokol et al, critical reviews in eukaryotic gene expression 6, 1, 29-57, 1996.
malone, journal of cellular biochemistry supplement 0, 19a, p206, 1995
sullivan, methods (orlando), 5, 1, 61-66, 1993.
satoshi et al., report of the fermentation research institute (Yatabe) 0, 75, p69-85, 1992
sullivan et al, journal of cellular biochemistry supplement 0, 17 part e, p23, 1993.
shaji et al., antiviral research 20, suppl. 1, p165, 1993.

thanks,
Melissa
11d05
mailboxes 11e12
AU 1635

Scientific and Technical
Information Center

DEC 13 RECD

PAT. & T.M. OFFICE

COMPLETED

9047199

TARGETED THERAPY FOR VIRAL HEPATITIS

Martin J. Schuster and George Y. Wu

Department of Medicine, Division of Gastroenterology-Hepatology, University of Connecticut School of Medicine, Farmington, CT 06030-1845, USA

CONTENTS

Summary	653
Introduction	653
Particle-Type Carriers as a Targeting Device	654
Liposomes	654
Endogenous lipid particles	655
Soluble Glycoprotein Carriers as a Targeting Device	655
Targeting of nucleoside analogs	655
Targeting of antisense oligonucleotides	656
Conclusions	657
Acknowledgements	657
References	657

Summary

New compounds for the therapy of chronic viral hepatitis, such as nucleoside analogs, antisense oligonucleotides or ribozymes, have been developed in the past several years. Although many are effective inhibitors of viral replication *in vitro*, efficacy *in vivo* and further clinical applications is often hampered by broad biodistribution and extrahepatic toxicity after systemic administration. Because the liver is the primary site of infection and damage in viral hepatitis, specific targeting of antiviral drugs to hepatocytes may be useful. For this purpose, particle-type carriers such as liposomes and endogenous lipid particles, as well as soluble drug carriers, especially ligands of the highly liver-selective asialoglycoprotein receptor, are currently under investigation. The use of these compounds could result in the efficient delivery of various new agents to the liver, and in the clinical application of new antiviral drugs in the future.

Introduction

Infections with hepatitis B virus (HBV), hepatitis C virus (HCV) and hepatitis D virus (HDV) cause a substantial burden on health care resources worldwide. Current estimates suggest that there are 200-300 million HBV carriers worldwide (1, 2), with the highest prevalence in Southeast Asia and sub-Saharan Africa, where up to 20% of the population is infected (3, 4). HDV infection only occurs in association with HBV. However, its prevalence is much lower and does not parallel HBV infection, probably accounting for less than 5% of chronic viral hepatitis (1, 5). It is found in approximately 5% of HBsAg carriers (6). HCV is the main cause of post-transfusion hepatitis. Its worldwide prevalence varies and is reflected in the prevalence of HCV antibodies in the blood donor population, ranging between 0.3% (in the United Kingdom and Scandinavia) and 3.6% (in Eastern Europe and parts of Africa). Because the prevalence in the general popu-

lation is thought to be higher, current estimates suggest that approximately 200 million people worldwide (7, 8) and 3.5 million or 1.4% of the population in the U.S. (1) have chronic HCV infection.

The clinical picture in patients with chronic infection varies from the healthy carrier state to acute or chronic liver disease leading to liver cirrhosis and liver failure. Chronic viral hepatitis due to HBV or HCV infection and liver cirrhosis are the main risk factors for development of hepatocellular carcinoma (9-11). The morbidity and mortality of chronic viral hepatitis have necessitated a prolonged search for effective therapy. Despite rapid advances in the understanding of the molecular biology of the viruses, only α -interferon is approved for therapy of HBV and HCV infection. Although useful in selected patients, the overall rate of sustained remission is only 30-40% for HBV (12), 15-30% for HCV (6, 13) and even lower for HDV (14), making the development of new approaches a major concern.

Conventional antiviral drugs such as nucleoside analogs or new compounds such as antisense oligonucleotides or ribozymes, which are effective inhibitors of viral replication *in vitro*, are often hampered *in vivo* because of broad biodistribution or extrahepatic toxicity. Drug targeting offers different advantages over conventional administration of drugs. High local concentrations of the drug can be achieved and distribution to tissues where its presence is not required can be avoided, thus circumventing many unwanted side effects. Specific delivery of antiviral drugs to the cell type where viral replication takes place is a challenging approach. Even though peripheral blood mononuclear cells have been suggested as extrahepatic reservoirs for HBV and HCV, recent results show little evidence for active replication (15, 16). Because the liver is the primary site of infection and damage in viral hepatitis, specific targeting of antiviral drugs to hepatocytes may be useful.

Basically two different approaches have been employed to achieve selective delivery of antiviral compounds (17, 18): 1) the use of prodrugs, which modulate the biodistribution characteristics and pharmacokinetic properties of the original agent to improve the availability of a drug at a desired cell type, and 2) carriers, both particulate and soluble, with the same rationale. This review will focus on the use of carriers as tools for drug targeting to the liver.

Particle-Type Carriers as a Targeting Device

The category of particle-type drug carriers includes liposomes, naturally occurring lipid particles, microspheres and nanoparticles. Yet, the specific delivery of antiviral agents to hepatocytes has been accomplished by the use of liposomes and lipid particles like LDL, HDL and chylomicrons.

Liposomes

Liposomes are microscopic vesicles consisting of one or multiple phospholipid bilayers surrounding one or multiple aqueous compartments. Liposome clearance from the circulation is a function of their size and surface composition. It must be noticed that the pores within the fenestrated wall of endothelial cells in the liver have a diameter of about 100 nm (19). Therefore, particles exceeding this size, as well as molecules larger than 250 kD can not pass into the space of Disse and, therefore, do not interact significantly with hepatocytes (18, 20). For this reason, liposomes larger than 100 nm are cleared by phagocytosis through Kupffer and endothelial cells. An advantage of liposomes as targeting device is the fact that drugs can be simply incorporated, either dissolved in the aqueous phase or associated with the lipid material, without covalent linkage (18). In addition, the encapsulated compound is protected against enzymatic degradation.

One of the first reports about drug delivery to hepatocytes by liposomes showed an enhanced antiviral effect of murine interferon entrapped in liposomes compared to the free compound against murine hepatitis virus in mice (21). The fate of intravenously injected liposomes depends largely on their lipid composition (22). By using small unilamellar liposomes consisting of cholesterol/egg phosphatidylcholine (1:1), 2/3 of the total dose injected intravenously in rats accumulated in the liver and 97% of this amount was found in parenchymal cells (23). To reduce the toxicity and to deliver a higher proportion of the administered drug to the liver, Hostetler and coworkers incorporated different antiviral nucleosides in liposomes consisting of phosphatidylcholine, phosphatidylglycerol and cholesterol. Liposomal phosphatidyl-dideoxycytidine (ddC) and liposomal phosphatidyl-dideoxythiacytidine (3TC, lamivudine) showed less cytotoxicity and only slightly reduced antiviral activity *in vitro* (24, 25) compared to the free drug, but had a 40-fold higher drug level in the liver after intraperitoneal administration in mice (24). Most recently, the same group showed that liposomal phosphatidyl-dideoxyguanosine (ddG), intraperitoneally injected in woodchucks, inhibited serum levels of woodchuck hepatitis virus (WHV) DNA 23- to 46-fold after 4 weeks of daily administration compared to 2.2- to 10.4-fold after treatment with free ddG (26).

To enhance the capacity of targeting liposomes to parenchymal liver cells, various ligands recognized by receptors on the liver cell surface were incorporated in the liposomal phospholipid bilayer. Examples for such targeting moieties are epidermal growth factor (27), lactosylceramide (28, 29), asialofetuin (30, 31), lactose mono-fatty acid esters (32,

33) and β -galactoside (34). By employing asialofetuin-coated liposomes to encapsulate interferon- γ , an increase of the inhibitory effect on the replication of HBV-DNA in Hep-HB107 cells compared to non-coated liposomes has been shown (31).

For many preparations, uptake by endothelial or Kupffer cells compared to parenchymal cells is still predominant, and there is no unanimity on the quantitative aspect of the differential uptake into different cell types in the liver (22). Liposomes with galactose residues are also recognized by Kupffer cells via the galactose-particle receptor (18), and the distribution between parenchymal and nonparenchymal liver cells is strongly size-dependent (35), with only very small liposomes with limited loading capacity or vesicles containing lactosylceramide (28) or lactose mono-fatty acid esters (32, 33) preferentially directed to parenchymal cells. Furthermore, while nucleosides, antisense-oligonucleotides or ribozymes act in the cytoplasm of the target cells, these modified liposomes enter cells through an endocytotic mechanism, followed by transfer to the degradative lysosomal compartment. Compounds that cannot escape this pathway may not be therapeutically active (36, 37). Presently, little is known about the intracellular fate of agents delivered to liver cells by targeted liposomes. Even though some encouraging results for the use of liposomes in the treatment of chronic viral hepatitis are emerging, further difficulties might arise with industrial large-scale production (38).

Endogenous lipid particles

Endogenous lipid particles, like LDL, HDL and chylomicrons, consist of lipid and apoprotein components. By glycosylation of the protein part or incorporation of glycolipids in the lipid part, cell-specific recognition by receptors other than the physiological receptors can be achieved. The incorporation of a triantennary galactose-terminated cholesterol derivative in HDL particles directed the conjugate to parenchymal liver cells (39). In a related work it was shown that the degree of lactosylation of LDL particles is important for the distribution of uptake between Kupffer and parenchymal cells, with a higher degree of lactosylation resulting in a preferential uptake by Kupffer cells (40). After lactosylation of the protein moiety of natural (41) or synthetic neo-HDL particles (42) and intravenous injection into rats, 95% and 80%, respectively, accumulated in the liver and uptake by parenchymal cells accounted for 98% and 90%, respectively, of the total liver uptake (41, 42). Since the preinjection of an excess amount of *N*-acetylgalactosamine or asialofetuin blocked the uptake in the liver, it was concluded that internalization is mediated by endocytosis via the asialoglyco-

protein receptor. More recently, recombinant chylomicrons were successfully used to deliver the nucleoside analog iododeoxyuridine via the largely liver-specific apolipoprotein E receptor (43) to parenchymal liver cells (44). Nevertheless, there are no reports about the antiviral activity of nucleoside analogs targeted to liver cells by the use of naturally occurring lipid particles or neolipids.

Soluble Glycoprotein Carriers as a Targeting Device

The major difference of soluble carriers compared to the former type of carrier is the smaller size of soluble carriers, with molecular weights below 200 kD. Therefore, they can easily pass through the fenestrated endothelial lining of liver capillaries and interact directly with hepatocytes. The asialoglycoprotein receptor (45), present in large numbers only on hepatocytes, binds galactose-terminated glycoproteins and neoglycoproteins with high affinity. Bound ligands are internalized by the cell via receptor-mediated endocytosis. Due to its specificity, the asialoglycoprotein receptor (AsGPr) has been exploited as a means to deliver drugs (46-48) and DNA (49-51) for therapeutic purposes, as well as diagnostic agents (52-54) to hepatocytes.

Targeting of nucleoside analogs

In 1979, Fiume *et al.* (55) demonstrated a specific delivery of trifluorothymidine (F3T), conjugated to asialofetuin, to hepatocytes. Conjugation was achieved by coupling the *N*-hydroxysuccinimidyl ester of F3T glutarate with the ϵ -amino groups of asialofetuin. It was shown to interact specifically with the AsGPr and to inhibit DNA synthesis in *Ectromelia* virus-infected liver cells selectively.

Subsequent studies by the same group have focused on adenine arabinofuranoside monophosphate (ara-AMP) and acyclovir monophosphate conjugates with galactosylated albumin (56-59). Albumin was galactosylated with lactose by reductive amination. The conjugates were synthesized with a phosphoramidate bond between the drug and ϵ -amino groups of the protein. The conjugates interacted specifically with the AsGPr and released the drug within liver cells (60). When prepared with homologous albumin, the conjugates were not immunogenic (61). Later the coupling reaction was modified to obtain predominantly monomeric conjugates to optimize specific delivery to parenchymal liver cells (62, 63). In woodchucks with viral hepatitis, conjugated ara-AMP or conjugated acyclovir inhibited viral replication at a dose 8- to 13-fold lower than the free drug (64). The appearance of intracellular vacuoles in mouse and rat liver cells after adminis-

tration of the conjugate was shown to result from lysosomal swelling (65). The effect disappeared after cessation of treatment and was prevented by lowering the dose. In the first studies in patients with chronic HBV infection, administration of the conjugate for 3-7 days showed a marked, but not sustained decrease of plasma HBV-DNA levels comparable to that of free drug, but at a dose 3-6 times lower (66, 67). No side effects were observed. In the latest study of the same group (68), 8 patients were treated with a higher dose over a period of 4 weeks. One patient developed small amounts of antibodies against the conjugate, but no other significant side effects were observed. All patients responded with a decrease of plasma HBV-DNA levels, but levels rose again after discontinuation of treatment.

The need for intravenous infusion of galactosylated araAMP prompted the search for other systems for targeting nucleoside analogs to hepatocytes. Conjugates with lactosylated poly-L-lysine also have been shown to target the AsGPr, and they were used to deliver ara-AMP (69), ribavirin and azidothymidine (70) to the liver after intramuscular administration in mice, and 5-iodo 2'-deoxyuridine after intravenous injection in rats (71). In woodchucks with viral hepatitis, ara-AMP conjugated to galactosylated poly-L-lysine showed comparable effects after intramuscular administration compared to ara-AMP conjugated with galactosylated albumin after intravenous administration (72). More recently, similar results were reported for a conjugate of ara-AMP with arabinogalactan, a naturally occurring polysaccharide and ligand of the AsGPr, when used to treat woodchuck hepatitis virus-infected woodchucks (73, 74).

Targeting of antisense oligonucleotides

In the last few years, antisense oligonucleotides and ribozymes have been explored as a new class of pharmaceuticals to inhibit the replication of hepatitis viruses. A number of antisense sequences which are capable of inhibiting the replication of hepatitis B (75-77) and hepatitis C (78, 79) viruses *in vitro* have been identified. Efficacy has also been observed with an antisense phosphorothioate DNA *in vivo* (80). Very recently, ribozymes have been shown to be effective against hepatitis B (81-83) and hepatitis C (84) gene expression. However, since cellular uptake of oligonucleotides is generally poor, and their susceptibility to degradation in plasma can be quite high, some form of targeting would be desirable for successful use of antisense and ribozyme strategies for therapy of viral hepatitis *in vivo*.

A system based on asialoglycoprotein-poly-L-lysine conjugates has been developed to target DNA or various other compounds to the liver via the

AsGPr (46-50). α_1 Acid glycoprotein, orosomucoid, was desialylated by treatment with neuraminidase to produce asialoorosomucoid (ASOR), a high-affinity ligand for the AsGPr. Poly-L-lysine (PL) was then covalently attached to the protein by carbodiimide-mediated amide bond formation. The resulting ASOR-PL conjugate bound the negatively charged DNA in a nondamaging electrostatic interaction (85) and protected it from nuclease degradation (86). The complex was selectively and rapidly internalized into hepatocytes by receptor-mediated endocytosis, and foreign genes were expressed *in vitro* (49) and *in vivo* (50).

The same strategy was used to prepare ASOR-PL complexes with an 21-mer antisense oligonucleotide complementary to the sequence of the polyadenylation signal of the HBV genome. By using a radioactive end-labeled species, it was determined that the oligo alone was taken up with a rate of 0.05 pmol/h/million cells by two hepatoma cell lines, HepG2 (AsGPr-positive) or SK Hep 1 (AsGPr-negative). However, the uptake of oligo conjugated to ASOR-PL was 10 times faster into HepG2 cells, but was not changed in SK Hep 1 cells. Coincubation with an excess asialoorosomucoid blocked the uptake. To show whether the targeted antisense has antiviral activity, the HepG2 2.2.15 cell line was used. This cell line possesses AsGPrs, is stably transfected with the complete HBV genome and secretes viral antigens as well as infectious virus particles. Administration of complexed antisense DNA blocked the expression of HBsAg in these cells and reduced the replication of viral DNA by about 80% compared to untreated controls. A complexed oligonucleotide with random sequence had no effect, and the antisense oligo DNA alone decreased the expression of surface antigen and viral replication by only approximately 30% (87).

In a subsequent investigation, ASOR-PL complexed to a 21-mer phosphorothioate antisense oligonucleotide against the polyadenylation region and adjacent upstream sequences of WHV was used to treat WHV-infected woodchucks. Animals were injected intravenously with ASOR-PL complexes containing 0.4 mg antisense for 5 consecutive days (total dose 2 mg/animal, 0.1 mg/kg/day). Although there was no difference in the levels of surface antigen between treated and untreated animals, a significant decrease in viral burden was observed. Treated animals showed a 1-2 log decrease in circulating viral DNA 25 days posttreatment. The decline lasted for approximately 2 weeks, after which there was a gradual rise in DNA levels. Antisense alone or a complex containing a random oligo DNA of the

same size and linkage failed to have any significant effect on viral DNA levels (88).

Targeted pretreatment of hepatocytes with the above antisense oligonucleotide complexed to ASOR-PL was used to prevent subsequent infection with HBV. Usually, it cannot be anticipated when an acute exposure to HBV will occur. However, after liver transplantation in patients infected with HBV, the grafts are invariably reinfected. Furthermore, there is an accelerated course in most cases. Protection of the graft by pretreatment could prevent reinfection. Pretreatment of Huh7 cells (AsGPr-positive) with ASOR-PL antisense complexes before lipofection with an HBV-plasmid (6.5 million copies of plasmid per cell) inhibited the amount of newly synthesized, core-associated viral DNA in Huh7 cells to undetectable levels, or less than 0.1 pg, as assessed by quantitative PCR. HBsAg, secreted by the cells into the medium, was inhibited in a dose-dependent manner by a maximum of 97%, and the inhibition lasted for 6 days. Pretreatment with unconjugated antisense or complexed random oligo showed no significant effects (89).

Very recently, a related targeting device, consisting of human adenovirus particles conjugated to N-acetyl-glucosamine-modified bovine serum albumin, streptavidin and PL, was used to deliver phosphorothioate-modified 16-mer antisense oligonucleotides to hepatocytes via the AsGPr. The oligonucleotide was directed against the encapsidation signal of the core gene. Chicken hepatoma cells (LHM) were transfected by complexed HBV-DNA. When the cells were treated with complexed oligonucleotide before and after treatment with complexed HBV-DNA, an approximately 80% inhibition of core-particulate-associated HBV-DNA levels was observed (90).

Conclusions

In the last few years, many new approaches have been developed to treat chronic viral hepatitis. These include novel nucleoside analogs, inducers of viral specific nucleases, interferon, thymic peptides, ribozymes and antisense oligonucleotides. However, toxic side effects in nontarget tissues are often dose-limiting, and a broad biodistribution reduces efficient concentrations in the liver. Targeting through the use of receptor-mediated endocytosis of these new agents could circumvent these drawbacks in the future.

Acknowledgements

M.J. Schuster is supported by a grant from the Deutsche Forschungsgemeinschaft (SCHU 1112/1-1). Part of the work described was supported by a grant from NIDDK (RO1-DK 42182 to GYW) and

a grant from Targ Tech Inc./Immune Response Corp. (to GYW). GYW holds equity in the Immune Response Corp.

References

1. Di Bisceglie, A.M., Hoofnagle, J.H. *Chronic viral hepatitis*. In: *Hepatology: A Textbook of Liver Disease*, 3rd Ed. Zakim, D., Boyer, T.D. (Eds.). WB Saunders: Philadelphia 1996.
2. Perrillo, R.P. *The management of chronic hepatitis B*. *Am J Med* 1994, 96 (Suppl. 1A): 34-9S.
3. Maynard, J.E., Kane, M.A., Alter, M.J., Hadler, S.C. *Control of hepatitis B by immunization: Global perspectives*. In: *Viral Hepatitis and Liver Disease*. Zuckerman, A.J. (Ed.). Alan R. Liss: New York 1988.
4. Kiire, C.F. *The epidemiology and prophylaxis of hepatitis B in sub-Saharan Africa*. *Prog Liver Dis* 1993, 11: 167-78.
5. Hoofnagle, J.H. *Therapy of acute and chronic viral hepatitis*. *Adv Intern Med* 1994, 39: 241-75.
6. Hara, M., Benfield, P. *Interferon- α 2a. A review of its pharmacological properties and therapeutic use in the management of viral hepatitis*. *Drugs* 1995, 50: 873-96.
7. Dhillon, A.P., Dusheiko, G.M. *Pathology of hepatitis C virus infection*. *Histopathology* 1995, 26: 297-309.
8. Zanetti, A.R., Tanzi, E., Romano, L., Mele, A. *Epidemiology and prevention of hepatitis type C in Italy*. *Res Virol* 1995, 146: 253-9.
9. Beasley, R.P., Hwang, L., Lin, C., Chien, C. *Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan*. *Lancet* 1981, 2: 1129-33.
10. Bruix, J., Barrera, J.M., Calvet, X. et al. *Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis*. *Lancet* 1989, 2: 1004-6.
11. Colombo, M., Kuo, G., Choo, Q.L. et al. *Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma*. *Lancet* 1989, 2: 1006-8.
12. Perrillo, R.P., Schiff, E.R., Davis, G.L. et al. *A randomized, controlled trial of interferon- α 2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B*. *New Engl J Med* 1990, 323: 295-301.
13. Davis, G.L. *Interferon treatment of chronic hepatitis C*. *Am J Med* 1994, 96 (Suppl. 1A): 41-6S.
14. Farci, P., Mandas, A., Coiana, A. et al. *Treatment of chronic hepatitis D with interferon- α 2a*. *New Engl J Med* 1994, 330: 88-94.
15. Koeck, J., Theilmann, L., Galle, P., Schlicht, H.J. *Hepatitis B virus nucleic acids associated with*

- human peripheral blood mononuclear cells do not originate from replicating virus. *Hepatology* 1996, 23: 405-13.
16. Lerat, H., Berby, F., Traubaud, M.A. et al. *Specific detection of hepatitis C virus minus strand RNA in hematopoietic cells*. *J Clin Invest* 1996, 97: 845-51.
 17. Meijer, D.K.F., Jansen, R.W., Molena, G. *Drug targeting systems for antiviral agents: Options and limitations*. *Antivir Res* 1992, 18: 215-58.
 18. Meijer, D.K.F., Molema, G. *Targeting of drugs to the liver*. *Semin Liver Dis* 1995, 15: 202-56.
 19. Wisse, E. *An electron microscopic study of the fenestrated endothelial lining of rat liver sinusoids*. *J Ultrastruct Res* 1970, 31: 125-50.
 20. Gregoriadis, G. *The carrier potential of liposomes in biology and medicine (I)*. *New Engl J Med* 1976, 295: 704-10.
 21. La Bonnardière, C. *Données préliminaires sur l'effet protecteur de l'interféron couplé a des liposomes dans le modele souris-virus de l'hépatite murine*. *Ann Microbiol* 1978, 129A: 397-402.
 22. Ghosh, P., Bachhawat, B. *Targeting of liposomes to hepatocytes*. In: *Liver Disease, Targeted Diagnosis and Therapy Using Specific Receptors and Ligands*. Wu, G., Wu, C. (Eds.). Marcel Dekker: New York 1991, 87-104.
 23. Spanjer, H.H., van Galen, M., Roerdink, F.H., Regts, J., Scherphof, G.L. *Intrahepatic distribution of small unilamellar liposomes as a function of liposomal lipid composition*. *Biochim Biophys Acta* 1986, 863: 224-30.
 24. Hostetter, K.Y., Korba, B.E., Sridhar, C.N., Gardner, M.F. *Antiviral activity of phosphatidyl-dideoxycytidine in hepatitis B-infected cells and enhanced hepatic uptake in mice*. *Antivir Res* 1994, 24: 59-67.
 25. Xie, H., Voronkov, M., Liotta, D.C. et al. *Phosphatidyl-2',3'-dideoxy-3'-thiacytidine: Synthesis and antiviral activity in hepatitis B- and HIV-1-infected cells*. *Antivir Res* 1995, 28: 113-20.
 26. Korba, B.A., Xie, H., Wright, K.N. et al. *Liver targeted antiviral nucleosides: Enhanced antiviral activity of phosphatidyl-dideoxyguanosine in woodchuck hepatitis virus infection in vivo*. *Hepatology* 1996, 23: 958-63.
 27. Ishii, Y., Aramaki, Y., Hara, T., Tsuchiya, S., Fuwa, T. *Preparation of EGF labeled liposomes and their uptake by hepatocytes*. *Biochem Biophys Res Commun* 1989, 160: 732-6.
 28. Spanjer, H.H., Scherphof, G.L. *Targeting of lactosylceramide-containing liposomes to hepatocytes in vivo*. *Biochim Biophys Acta* 1983, 734: 40-7.
 29. Soriano, P., Dijkstra, J., Legrand, A. et al. *Targeted and nontargeted liposomes for in vivo transfer to rat liver cells of a plasmid containing the preproinsulin I gene*. *Proc Natl Acad Sci USA* 1983, 80: 7128-31.
 30. Ishihara, H., Hara, T., Aramaki, Y., Tsuchiya, S., Hosoi, K. *Preparation of asialofetuin-labeled liposomes with encapsulated human interferon- γ and their uptake by isolated rat hepatocytes*. *Pharm Res* 1990, 7: 542-6.
 31. Ishihara, H., Hayashi, Y., Hara, T., Aramaki, Y., Tsuchiya, S., Koike, K. *Specific uptake of asialofetuin-tacked liposomes encapsulating interferon- γ by human hepatoma cells and its inhibitory effect on hepatitis B virus replication*. *Biochem Biophys Res Commun* 1991, 174: 839-45.
 32. Yamauchi, H., Kikuchi, H., Sawada, M., Tomikawa, M., Hirota, S. *Characterization and tissue distribution of liposomes containing lactose mono-fatty acid derivatives*. *J Microencapsul* 1994, 11: 179-88.
 33. Yamauchi, H., Kikuchi, H., Sawada, M., Tomikawa, M., Hirota, S. *Selective uptake of liposomes containing lactose mono-fatty acid derivatives by hepatic parenchymal cells*. *J Microencapsul* 1994, 11: 287-96.
 34. Ghosh, P., Das, P.K., Bachhawat, B.K. *Targeting of liposomes towards different cell types of rat liver through the involvement of liposomal surface glycosides*. *Arch Biochem Biophys* 1982, 213: 266-70.
 35. Schlepper-Schaefer, J., Huelsmann, D., Djovkar, A. et al. *Endocytosis via galactose receptors in vivo. Ligand size directs uptake by hepatocytes and/or liver macrophages*. *Exp Cell Res* 1986, 165: 494-506.
 36. Szoka, F.C. *The future of liposomal drug delivery*. *Biotech Appl Biochem* 1990, 12: 496-500.
 37. Machy, P., Leserman, L. *Endocytosis of cell surface molecules and intracellular delivery of materials encapsulated in targeted liposomes*. In: *Targeting of Drugs II: Optimization Strategies*. Gregoriadis, G., Allison, A.C., Poste, G. (Eds.). Plenum Press: New York 1990, 77-86.
 38. Schwendener, R.A. *The preparation of large volumes of sterile liposomes for clinical applications*. In: *Liposome Technology*, 2nd Ed., Vol. I. Gregoriadis, G. (Ed.). CRC Press: Boca Raton 1993, 487-500.
 39. Van Berkel, T.J.C., Kruijt, J.K., Kempen, H.J.M. *Specific targeting of high density lipoproteins to liver hepatocytes by incorporation of a trisgalactoside-terminated cholesterol derivative*. *J Biol Chem* 1985, 260: 12203-7.

40. Bijsterbosch, M.K., van Berkel, T.J.C. *Uptake of lactosylated low-density lipoprotein by galactose-specific receptors in rat liver*. *Biochem J* 1990, 270: 233-9.
41. Bijsterbosch, M.K., van Berkel, T.J.C. *Lactosylated high density lipoprotein: A potential carrier for the site-specific delivery of drugs to parenchymal liver cells*. *Mol Pharmacol* 1992, 41: 404-11.
42. Schouten, D., van der Kooij, M., Muller, J., Pieters, M.N., Bijsterbosch, M.K., van Berkel, T.J.C. *Development of lipoprotein-like particles for drug targeting: Neo-high density lipoproteins*. *Mol Pharmacol* 1993, 44: 486-92.
43. Hoeg, J.M., Demosky, S.J. Jr. *Distinct hepatic receptors for low density lipoprotein and apolipoprotein E in humans*. *Science* 1985, 227: 759-61.
44. Rensen, P.C.N., van Dijk, M.C.M., Havenaar, E.C., Bijsterbosch, M.K., Kruijt, J.K., van Berkel, T.J.C. *Selective liver targeting of antivirals by recombinant chylomicrons - A new approach to hepatitis B*. *Nature Med* 1995, 1: 221-5.
45. Ashwell, G., Morell, A.G. *The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins*. *Adv Enzymol Relat Areas Mol Biol* 1974, 41: 99-128.
46. Wu, G.Y., Wu, C.H., Stockert, R.J. *Model of specific rescue of normal hepatocytes during methotrexate treatment of hepatic malignancy*. *Proc Natl Acad Sci USA* 1983, 80: 3078-80.
47. Wu, G.Y., Wu, C.H., Rubin, M.I. *Acetaminophen hepatotoxicity and targeted rescue: A model of specific chemotherapy for hepatocellular carcinoma*. *Hepatology* 1985, 5: 709-13.
48. Wu, G.Y., Keegan-Rogers, V., Franklin, S., Midford, S., Wu, C.H. *Targeted antagonism of galactosamine toxicity in normal rat hepatocytes in vitro*. *J Biol Chem* 1988, 263: 4719-23.
49. Wu, G.Y., Wu, C.H. *Receptor-mediated in vitro gene transformation by a soluble DNA carrier system*. *J Biol Chem* 1987, 262: 4429-32.
50. Wu, G.Y., Wu, C.H. *Receptor-mediated gene delivery and expression in vivo*. *J Biol Chem* 1988, 263: 14621-4.
51. Wu, C.H., Wilson, J.M., Wu, G.Y. *Targeting genes: Delivery and persistent expression of a foreign gene driven by mammalian regulatory elements in vivo*. *J Biol Chem* 1989, 264: 16985-7.
52. Vera, D.R., Krohn, K.A., Stadalnik, R.C., Scheibe, P.O. *Tc-99m-galactosylneoglycoalbumin: In vivo characterization of receptor-mediated binding to hepatocytes*. *Radiology* 1984, 151: 191-6.
53. Galli, G., Maini, C.L., Orlando, P., Deleide, G., Valle, G. *A radiopharmaceutical for the study of the liver: 99m-Tc-DTPA-asialoorosomucoid*. *J Nucl Med Allied Sci* 1988, 32: 110-26.
54. Gallez, B., Lacour, V., Demeure, R. et al. *Spin labelled arabinogalactan as MRI contrast agent*. *Magn Reson Imaging* 1994, 12: 61-9.
55. Fiume, L., Mattioli, A., Balborli, P.G. et al. *Enhanced inhibition of virus DNA synthesis in hepatocytes by trifluorothymidine coupled to asialofetuin*. *FEBS Lett* 1979, 103: 47-51.
56. Fiume, L., Busi, C., Mattioli, A., Balboni, P.G., Barbanti-Brodano, G. *Hepatocyte targeting of adenine-9- β -D-arabinofuranoside 5'-monophosphate (ara-AMP) coupled to lactosaminated albumin*. *FEBS Lett* 1981, 129: 261-4.
57. Fiume, L., Bassi, B., Busi, C., Mattioli, A., Spinosa, G. *Drug targeting in antiviral chemotherapy. A chemically stable conjugate of 9- β -D-arabinofuranosyl-adenine 5'-monophosphate with lactosaminated albumin accomplishes a selective delivery of the drug to liver cells*. *Biochem Pharmacol* 1986, 35: 967-72.
58. Fiume, L., Balboni, P.G., Bassi, B., Busi, C., Mattioli, A., Spinosa, G. *9- β -D-arabinofuranosyl-adenine 5'-monophosphate coupled to lactosaminated albumin is not metabolized in mouse bloodstream*. *Pharm Acta Helv* 1986, 61: 342-4.
59. Fiume, L., Bassi, B., Bongini, A. *Conjugates of 9- β -D-arabinofuranosyladenine 5'-monophosphate (ara-AMP) with lactosaminated albumin. Characterization of the drug-carrier bonds*. *Pharm Acta Helv* 1988, 63: 137-9.
60. Fiume, L., Busi, C., Mattioli, A., Spinelli, C., Spinosa, G., Bongini, A. *A conjugate of acyclovir monophosphate with lactosaminated albumin releases the phosphorylated drug in liver cells*. *Naturwissenschaften* 1989, 76: 74-6.
61. Fiume, L., Busi, C., Preti, P., Spinosa, G. *Conjugates of ara-AMP with lactosaminated albumin: A study on their immunogenicity in mouse and rat*. *Cancer Drug Deliv* 1987, 4: 145-50.
62. Janssen, R.W., Kruijt, J.K., van Berkel, T.J.C., Meijer, D.K.F. *Coupling of the antiviral drug ara-AMP to lactosaminated albumin leads to specific uptake in rat and human hepatocytes*. *Hepatology* 1993, 18: 146-52.
63. Fiume, L., Busi, C., Di Stefano, G., Mattioli, A. *Coupling of antiviral nucleoside analogs to lactosaminated human albumin by using the imidazolides of their phosphoric esters*. *Anal Biochem* 1993, 212: 407-11.
64. Ponzetto, A., Fiume, L., Forzani, B. et al. *Adenine arabinoside monophosphate and acyclovir*

- monophosphate coupled to lactosaminated albumin reduce woodchuck hepatitis virus viraemia at doses lower than do the unconjugated drugs. *Hepatology* 1991, 14: 16-24.
65. Fiume, L., Betts, C.M., Busi, C. et al. The pathogenesis of vacuoles produced in rat and mouse liver cells by a conjugate of adenine arabinoside monophosphate with lactosaminated albumin. *J Hepatol* 1992, 15: 314-22.
 66. Fiume, L., Bonino, F., Mattioli, A. et al. Inhibition of hepatitis B virus replication by vidarabine monophosphate conjugated with lactosaminated serum albumin. *Lancet* 1988, 2: 13-5.
 67. Torrani Cerenzia, M.R., Fiume, L., Busi, C. et al. Inhibition of hepatitis B virus replication by adenine arabinoside monophosphate coupled to lactosaminated albumin. Efficacy and minimal active dose (letter). *J Hepatol* 1994, 20: 307-9.
 68. Torrani Cerenzia, M.R., Fiume, L., de Bernardi Venon, W. et al. Adenine arabinoside monophosphate coupled to lactosaminated albumin administered for 4 weeks in patients with chronic type B hepatitis decreased viremia without producing significant side effects. *Hepatology* 1996, 23: 657-61.
 69. Fiume, L., Di Stefano, G., Busi, C., Mattioli, A. A conjugate of lactosaminated poly-L-lysine with adenine arabinoside monophosphate, administered to mice by intramuscular route, accomplishes a selective delivery of the drug to the liver. *Biochem Pharmacol* 1994, 47: 643-50.
 70. Di Stefano, G., Busi, C., Mattioli, A., Fiume, L. Selective delivery to the liver of antiviral nucleoside analogs coupled to a high molecular mass lactosaminated poly-L-lysine administered to mice by intramuscular route. *Biochem Pharmacol* 1995, 49: 1769-75.
 71. Biessen, E.A., Beutling, D.M., Vietsch, H., Bijsterbosch, M.K., van Berkel, T.J.C. Specific targeting of the antiviral drug 5-iodo 2'-deoxyuridine to the parenchymal liver cell using lactosylated poly-L-lysine. *J Hepatol* 1994, 21: 806-15.
 72. Fiume, L., Di Stefano, G., Busi, C. et al. Inhibition of woodchuck hepatitis virus replication by adenine arabinoside monophosphate coupled to lactosaminated poly-L-lysine administered by intramuscular route. *Hepatology* 1995, 22: 1072-7.
 73. Groman, E.V., Enriquez, P.M., Jung, C., Josephson, L. Arabinogalactan for hepatic drug delivery. *Bioconjug Chem* 1994, 5: 547-56.
 74. Enriquez, P.M., Jung, C., Josephson, L., Tennant, B.C. Conjugation of adenine arabinoside 5'-monophosphate to arabinogalactan synthesis, characterization, and antiviral activity. *Bioconjug Chem* 1995, 6: 195-202.
 75. Goodarzi, G., Gross, S.C., Tewari, A., Watabe, K. Antisense oligodeoxynucleotides inhibit the expression of the gene for hepatitis B virus surface antigen. *J Gen Virol* 1990, 71: 3021-5.
 76. Blum, H.E., Galun, E., von Weizsaecker, F., Wands, J.R. Inhibition of hepatitis B virus by antisense oligodeoxynucleotides. *Lancet* 1991, 337: 1230.
 77. Korba, B.E., Gerin, J.L. Antisense oligonucleotides are effective inhibitors of hepatitis B virus replication in vitro. *Antivir Res* 1995, 28: 225-42.
 78. Wakita, T., Wands, J.R. Specific inhibition of hepatitis C virus expression by antisense oligodeoxynucleotides. In vitro model for selection of target sequence. *J Biol Chem* 1994, 269: 14205-10.
 79. Alt, M., Renz, R., Hofschneider, P.H., Paumgartner, G., Caselmann, W.H. Specific inhibition of hepatitis C viral gene expression by antisense phosphorothioate oligodeoxynucleotides. *Hepatology* 1995, 22: 707-17.
 80. Offensperger, W.B., Offensperger, S., Walter, E. et al. In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligonucleotides. *EMBO J* 1993, 12: 1257-62.
 81. Von Weizsaecker, F., Blum, H.E., Wands, J.R. Cleavage of hepatitis B virus RNA by three ribozymes transcribed from a single DNA template. *Biochem Biophys Res Commun* 1992, 189: 743-8.
 82. Beck, J., Nassal, M. Efficient hammerhead ribozyme-mediated cleavage of the structured hepatitis B virus encapsidation signal in vitro and in cell extracts, but not in intact cells. *Nucleic Acids Res* 1995, 23: 4954-62.
 83. Ruiz, J., Wu, C.H., Ito, Y., Wu, G.Y. Design and preparation of a novel multimeric self-cleaving ribozyme. *BioTechniques*, in press.
 84. Sakamoto, N., Wu, C.H., Wu, G.Y. Intracellular cleavage of hepatitis C virus RNA and inhibition of viral protein translation by hammerhead ribozymes. *J Clin Invest*, in press.
 85. Chang, C., Weiskopf, M., Li, H.G. Conformational studies of nucleoprotein circular dichroism of deoxyribonucleic acid base pairs bound by polylysine. *Biochemistry* 1973, 12: 3028-32.
 86. Chiou, H.C., Tangco, M.V., Levine, S.M. et al. Enhanced resistance to nuclease degradation of nucleic acids complexed to asialoglycoprotein-polylysine carriers. *Nucleic Acids Res* 1994, 22: 5439-46.

87. Wu, G.Y., Wu, C.H. *Specific inhibition of hepatitis B viral gene expression in vitro by targeted antisense oligonucleotides.* J Biol Chem 1992, 267: 12436-9.
88. Bartholomew, R.M., Carmichael, E.P., Findeis, M A., Wu, C.H., Wu, G.Y. *Targeted delivery of antisense DNA in woodchuck hepatitis virus-infected woodchucks.* J Viral Hepat 1995, 2: 273-8.
89. Nakazono, K., Ito, Y., Wu, C.H., Wu, G.Y. *Inhibition of hepatitis B virus replication by targeted pretreatment of complexed antisense DNA in vitro.* H patology 1996, 23: 1297-303.
90. Madon, J., Blum, H.E. *Receptor-mediated delivery of hepatitis B virus DNA and antisense oligodeoxynucleotides to avian liver cells.* H patology 1996, 24: 474-81.